We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical

300 hedge funds and large institutions have $3.25B invested in Ultragenyx Pharmaceutical in 2025 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 128 increasing their positions, 104 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more funds holding in top 10

Funds holding in top 10: 5 → 7 (+2)

32% more capital inflows, than outflows

Capital inflows: $396M | Capital outflows: $301M

23% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 104

2.35% more ownership

Funds ownership: 94.7% → 97.05% (+2.4%)

4% more call options, than puts

Call options by funds: $43.9M | Put options by funds: $42.2M

4% less funds holding

Funds holding: 313 → 300 (-13)

30% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 44

Holders
300
Holders Change
-13
Holders Change %
-4.15%
% of All Funds
4.01%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.09%
New
31
Increased
128
Reduced
104
Closed
44
Calls
$43.9​M
Puts
$42.2​M
Net Calls
+$1.65​M
Net Calls Change
+$8.06​M

RARE Hedge Fund Activity: Q1 2025 in Review

300 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2025, worth a combined $3.25B — down 12% from $3.68B a quarter earlier.

Sellers outnumbered buyers: 44 funds closed out of RARE and 31 opened new positions — a net loss of 13 holders — while 104 trimmed existing stakes and 128 added.

The largest buyer was Adage Capital Partners, adding an estimated $40.2M. The largest seller was Vestal Point Capital, cutting an estimated $41.6M.

  • 300 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2025, down from 313 in Q4 2024.
  • Funds reported $3.25B of Ultragenyx Pharmaceutical stock for Q1 2025, down 12% quarter-over-quarter.
  • 31 funds opened new Ultragenyx Pharmaceutical positions in Q1 2025 and 44 closed out, a net change of -13 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q1 2025 was Adage Capital Partners, an estimated $40.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q1 2025 was Vestal Point Capital, an estimated $41.6M sold.

Based on aggregated 13F filings for Q1 2025.